Mainz Biomed, a molecular genetics diagnostic company specializing in the early detection of cancer, announced a collaborative agreement with Thermo Fisher Scientific Inc. through its subsidiary Life Technologies Corporation.
Combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer live longer and control their disease better than with the standard treatment drug regorafenib, according to a study led by UCLA investigators.
